Scope of this summary
Newborn infants at 35 or more weeks of gestation during birth hospitalization and early follow-up, matching the population of the current AAP guideline. Infants born before 35 weeks, prolonged conjugated hyperbilirubinemia, neonatal intensive-care complexity and liver or metabolic disease require separate protocols.
sources for this section:AAP hyperbilirubinemia 2022
The Bottom Line
- Measure bilirubin rather than relying on visual assessment alone. Obtain a transcutaneous or total serum bilirubin between 24 and 48 hours after birth or before discharge if earlier, and measure immediately when jaundice is seen in the first 24 hours.
- Use total serum bilirubin as the definitive value for phototherapy and escalation decisions, interpreted by postnatal age in hours, gestational age and the presence of hyperbilirubinemia neurotoxicity risk factors.
- Assess feeding, latch or milk transfer, weight trajectory, urine and stool output and family support because suboptimal intake can accelerate bilirubin rise; protect breastfeeding while providing individualized lactation and supplementation support when medically indicated.
- Investigate hemolysis and other causes when bilirubin rises rapidly, appears very early or approaches treatment thresholds, including maternal and infant blood-group information, direct antiglobulin testing when indicated and consideration of G6PD deficiency.
- Base discharge follow-up on how far the measured bilirubin lies below the hour-specific phototherapy threshold together with age, feeding, weight loss, gestation, neurotoxicity risks and the family鈥檚 ability to obtain timely reassessment.
sources for this section:AAP hyperbilirubinemia 2022
Practical clinical workflow
1
Review gestational age, birth trauma, feeding, maternal and infant blood groups, family or ancestry history of significant neonatal jaundice or G6PD deficiency, sibling phototherapy and medicines or illness that increase risk.
2
Perform a structured examination for extent of jaundice, hydration, bruising or cephalohematoma, pallor, hepatosplenomegaly, tone and alertness, while recognizing that skin color and lighting make visual estimation unreliable.
3
Plot the current total serum bilirubin against the official AAP decision support for the infant鈥檚 exact age, gestation and risk factors; arrange phototherapy, repeat measurement or routine follow-up from that verified result rather than from a copied static number.
4
During treatment, monitor bilirubin trajectory, temperature, hydration and feeding, evaluate the cause and use the AAP rebound-risk approach when planning discontinuation and post-phototherapy testing.
5
At every transition, document the last bilirubin value and time, distance from treatment threshold, risk factors, feeding and weight assessment, exact follow-up appointment and who owns pending laboratory results.
sources for this section:AAP hyperbilirubinemia 2022
Safety boundaries and escalation
- Lethargy, poor suck, abnormal high-pitched cry, hypotonia or hypertonia, arching, apnea or seizure may indicate acute bilirubin encephalopathy and requires immediate neonatal intensive-care and exchange-transfusion escalation.
- A bilirubin at or approaching the AAP escalation-of-care threshold is a medical emergency; obtain expert neonatal support and follow the official current chart rather than waiting for routine outpatient repeat testing.
- Jaundice in the first 24 hours, a rapid bilirubin rise or anemia raises concern for hemolysis and requires urgent measurement and cause assessment even if the infant otherwise appears well.
- Dark urine, pale stool or persistent jaundice can indicate conjugated hyperbilirubinemia and hepatobiliary disease; measure direct bilirubin and use the appropriate cholestasis pathway rather than continuing physiologic-jaundice reassurance.
sources for this section:AAP hyperbilirubinemia 2022
Localization
AAP 2022 is the governing national pediatric guideline for infants born at least 35 weeks. Treatment lines differ by gestational age, postnatal hour and neurotoxicity risk; use validated AAP-based decision support together with the hospital鈥檚 newborn screening and G6PD policies and a concrete outpatient follow-up network.
sources for this section:AAP hyperbilirubinemia 2022
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- American Academy of Pediatrics Subcommittee on HyperbilirubinemiaClinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of GestationDOI 10.1542/peds.2022-058859 路 published 2022-08-05 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.